ClinicalTrials.gg
CompletedNCT04969224Updated Sep 24, 2025Results posted

A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 19 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
16th of 23
82 · median 120
Started
2021
with 2 others
Phase 3
19 of 23
none open now
Registered
15th of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 16th largest by enrollment, is one of 3 that started in 2021, is one of 19 in phase 3, and was the 15th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (FEV1) value ≥30% and ≤90% predicted
  • Heterozygous for CF transmembrane conductance regulator gene (CFTR) F508del mutation and a minimal function mutation (F/MF genotypes)

Key Exclusion Criteria:

  • liver cirrhosis
  • Solid organ or hematological transplantation
  • Non-ambulatory status
  • Lung infection with organisms associated with a more rapid decline in pulmonary status

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    ELX/TEZ/IVA

    Participants received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period approximately 13 weeks.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed dose combination (FDC) tablet for oral administration.

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    Tablet for oral administration.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12

    Percent reduction in cough frequency was analyzed with a mixed effects model for repeated measures (MMRM), with change from baseline at each post-baseline visit on the natural log scale as the dependent variable. The percent reduction was estimated as 100% × (1-exponential form of LS mean change estimate from the MMRM).

    Time frame: Baseline, Week 8 through Week 12

Secondary outcomes

  1. Absolute Change From Baseline in Total Step Count Per Day to the Average of Week 8 Through Week 12

    Time frame: Baseline, Week 8 through Week 12

07

Results

Posted Oct 3, 2023

Participant flow

Participant flow — Overall Study
MilestoneELX/TEZ/IVA
Started82
Completed80
Not completed2
Withdrew: Adverse event1
Withdrew: Enrolled but never dosed1

Outcome measures

PrimaryPercent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12

Percent reduction in cough frequency was analyzed with a mixed effects model for repeated measures (MMRM), with change from baseline at each post-baseline visit on the natural log scale as the dependent variable. The percent reduction was estimated as 100% × (1-exponential form of LS mean change estimate from the MMRM).

Time frame:
Baseline, Week 8 through Week 12
Reported as:
Least squares mean · percent reduction
Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12
percent reductionELX/TEZ/IVA
Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 1291.7 (89.2 to 93.6)
SecondaryAbsolute Change From Baseline in Total Step Count Per Day to the Average of Week 8 Through Week 12
Time frame:
Baseline, Week 8 through Week 12
Reported as:
Least squares mean · step count per day
Absolute Change From Baseline in Total Step Count Per Day to the Average of Week 8 Through Week 12
step count per dayELX/TEZ/IVA
Absolute Change From Baseline in Total Step Count Per Day to the Average of Week 8 Through Week 12637.56 (298.16 to 976.96)

Adverse events

Collected over Day 1 up to Week 17. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ELX/TEZ/IVA0/81 (0%)2/81 (2.5%)56/81 (69.1%)
Most frequent serious events
Most frequent serious events
EventELX/TEZ/IVA
PancreatitisGastrointestinal disorders1/81
AnxietyPsychiatric disorders1/81
Most frequent other events
Showing 10 of 11
Most frequent other events
EventELX/TEZ/IVA
HeadacheNervous system disorders14/81
COVID-19Infections and infestations13/81
NasopharyngitisInfections and infestations13/81
DiarrhoeaGastrointestinal disorders11/81
Abdominal painGastrointestinal disorders8/81
Oropharyngeal painRespiratory, thoracic and mediastinal disorders8/81
Abdominal pain upperGastrointestinal disorders7/81
Upper respiratory tract infectionInfections and infestations7/81
CoughRespiratory, thoracic and mediastinal disorders6/81
Nasal congestionRespiratory, thoracic and mediastinal disorders5/81

Baseline characteristics

All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.

Age, Continuous
Age, Continuous(years)ELX/TEZ/IVA
Mean25.7 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)ELX/TEZ/IVA
Female37
Male44
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ELX/TEZ/IVA
Hispanic or Latino3
Not Hispanic or Latino78
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ELX/TEZ/IVA
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White81
More than one race0
Unknown or Not Reported0
08

Study locations

19 sites
  • Royal Adelaide Hospital
    Adelaide, Australia
  • The Prince Charles Hospital
    Chermside, Australia
  • Alfred Hospital
    Melbourne, VIC, Australia
  • Institute for Respiratory Health
    Nedlands, Australia
  • Telethon Kids Institute
    Nedlands, Australia
  • The Royal Children's Hospital
    Parkville, VIC, Australia
  • Mater Adult Hospital
    South Brisbane, Australia
  • Queensland Children's Hospital
    South Brisbane, Australia
  • Cliniques Universitaires de Bruxelles Hopital Erasme
    Brussels, Belgium
  • Universitair Ziekenhuis Brussel - Campus Jette
    Brussels, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, Belgium
  • University of Calgary Medical Clinic of the Foothills Medical Centre
    Calgary, Canada
  • University of Alberta Hospital, Edmonton Clinic
    Edmonton, Canada
  • Queen Elizabeth II Health Sciences Center
    Halifax, Canada
  • Hospital Universitari Vall d Hebron
    Barcelona, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, Spain
  • Corporacio Sanitaria Parc Tauli - Sabadell Hospital Universitari
    Sabadell, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jul 2022, 9 months.

Results were first posted in Oct 2023, 1 year 2 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 9 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2021
First posted
Jul 20, 2021
StartActual
Oct 12, 2021
Primary completionActual
Jul 26, 2022
CompletionActual
Jul 26, 2022
Results first posted
Oct 3, 2023
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04969224
Responsible party
Sponsor
First posted
Jul 20, 2021
Start date
Oct 12, 2021
Primary completion
Jul 26, 2022
Completion
Jul 26, 2022
Results posted
Oct 3, 2023
Last update
Sep 24, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion